MIMEDX announced second quarter 2026 net sales of $64 million, a 35% decline from the prior year, and separately unveiled a definitive agreement to acquire Sanara MedTech in a cash-and-stock deal valued at approximately $350 million. Surgical product sales grew 15% year-over-year, led by AMNIOFIX and AMNIOEFFECT, while Wound sales fell 61% due to Medicare reimbursement changes that took effect on January 1. The company reported a net loss of $15 million for the quarter, compared to net income of $10 million a year earlier, and held $136 million in cash and equivalents as of June 30. MIMEDX reiterated its full-year 2026 net sales guidance of $260 to $290 million and expects Adjusted EBITDA to approach breakeven. Under the Sanara acquisition terms, Sanara shareholders will receive $33.00 in cash and 0.4735 shares of MIMEDX common stock per share, representing a 46% premium to Sanara’s 30-day volume-weighted average price, with the transaction expected to close by year-end subject to shareholder and regulatory approvals.
MiMedx Group IncNet sales fell 35% and net loss of $15 million vs prior year profit.
Sanara Medtech IncAcquisition at 46% premium to 30-day VWAP.